Gene Therapy Research Report 2018: Focus on Technologies …PR Newswire (press release)Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an ex… Continue reading
Medical XpressTeam paves the way to the use of immunotherapy to treat aggressive colon tumorsMedical XpressIn a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. Ho… Continue reading
News-Medical.netNew NK cell-based immunotherapy effective against several types of leukemiaNews-Medical.netResearchers at Karolinska Institutet in Sweden have explored NK cell-based immunotherapy on patients with treatment-resistant leukemia. The study… Continue reading
Global Gene Therapy Technologies, Markets and Companies 2017-2027GlobeNewswire (press release)The report also discusses the adverse effects of various vectors, safety regulations and ethical aspects of gene therapy including gene editing and germline g… Continue reading
News-Medical.netScientists discover adult endothelial stem cells capable of generating fully functional blood vesselsNews-Medical.netThe proper function of blood vessels is essential to life: blood vessels are responsible for transporting oxygen-rich r… Continue reading
News-Medical.netScientists discover adult endothelial stem cells capable of generating fully functional blood vesselsNews-Medical.netThe proper function of blood vessels is essential to life: blood vessels are responsible for transporting oxygen-rich r… Continue reading
Nasdaq |
Oxford BioMedica wins second $100 mln gene therapy contract
Nasdaq LONDON, Feb 15 (Reuters) – Britain’sOxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion. Oxford Bio said on Thursday it … Oxford BioMedica share price rises on $100m gene therapy deal with BioverativCity A.M. Oxford BioMedica signs agreement with BioverativStock Market Wire |
City A.M. |
Oxford BioMedica wins second $100 million gene therapy contract
Reuters The deal follows a similar $100 million contract last year to supply lentiviral vectors, which are used to deliver DNA into cells, for Novartis’s pioneering leukemia treatment Kymriah. Oxford Bio, which listed in London in 1996 after being spun out of … Oxford BioMedica share price rises on $100m gene therapy deal with BioverativCity A.M. Oxford BioMedica signs agreement with BioverativStock Market Wire Oxford BioMedica Inks Potential USD100 Million Deal With BioverativLondon South East (blog) Proactive Investors UK all 9 news articles » |